AFMD Affimed N.V.

-0.32  -9%
Previous Close 3.73
Open 3.7
Price To Book 5.25
Market Cap 212879207
Shares 62,427,920
Volume 1,200,302
Short Ratio
Av. Daily Volume 1,012,661

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data at ASH noted 46% CR; 88% ORR.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
Hodgkin Lymphoma - Cancer
Phase 1b/2a data at ASH 2018 noted 4/9 ORs including 1CR.
CD30-positive lymphoma
Phase 1 trial placed on clinical hold - October 8, 2018.
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
Phase 2 trial to be initiated 1H 2019.
Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF)

Latest News

  1. Edited Transcript of AFMD earnings conference call or presentation 7-Nov-18 1:30pm GMT
  2. Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day
  3. Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors
  4. Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City
  5. My Stock of the Week: Affirmed N.V.
  6. Our Take On Affimed NV’s (NASDAQ:AFMD) CEO Salary
  7. Report: Exploring Fundamental Drivers Behind Affimed N.V, Sensus Healthcare, Lifetime Brands, SigmaTron International, Salem Media Group, and Origin Agritech — New Horizons, Emerging Trends, and Upcoming Developments
  8. Implied Volatility Surging for Affimed (AFMD) Stock Options
  9. Affimed to Present at the Jefferies 2018 London Healthcare Conference
  10. Affirmed Therapeutics (AFMD) Reports Q3 Loss, Tops Revenue Estimates
  11. Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress
  12. Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting
  13. Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018
  14. Company News For Oct 10, 2018
  15. Affimed Down After Clinical Hold on Two Early-Stage Studies
  16. [$$] Stocks to Watch: Alphabet, Exxon, Papa John's, Tesla
  17. Stocks making the biggest move premarket: TSLA, PZZA, MSFT, WMT & more
  18. The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
  19. After-hours buzz: TSLA, EW & more